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Omega-3 fatty acid dietary supplementation in systemic lupus erythem-
atosus. The effect of dietary fish oil (Omega-3 fatty acids—eicosapen-
tenoic acid [EPA] and docosahexaenoic acid [DHA] on several mech-
anisms involved in immune, inflammatory and atherosclerotic vascular
disease was determined in 12 subjects with systemic lupus erythema-
tosus (SLE) and nephritis. These out-patients supplemented their usual
diet for five weeks with daily doses of 6 g of fish oil, followed by a
five-week washout period, then five weeks of 18 g of fish oil daily. The
platelet EPA content rose six-fold with the lower and 15-fold with the
higher dose of fish oil, and similar changes occurred to the platelet DHA
content. The platelet arachidonic acid incorporation was reduced by 16
and 20%, respectively. These changes were associated with a reduction
in collagen-induced platelet aggregation and an increase in red cell
flexibility and a decrease in whole blood viscosity. Prostacyclin (PGI2)
production was unaffected by the fish oil, but P013 formation correlated
with its administration and dosage. Neutrophil leukotriene B., release
was reduced 78 and 42%, respectively, by the low and higher doses of
fish oil. The higher fish oil dose induced a 38% decrease in triglyceride
and a 39% reduction in VLDL cholesterol associated with a 28% rise in
HDL cholesterol. The fish oil had no effect on immune complex or
anti-DNA antibody titer, albuminuria, intraplatelet serotonin or
serotonin release from platelets. We conclude that in patients with
lupus nephritis, dietary supplementation with fish oil affects the mech-
anisms involved in inflammatory and atherosclerotic vascular disease.
The prognosis of patients with lupus nephritis continues to
improve [1—4]. Much of the success is attributed to a more
rational application of therapeutic agents which alter immune
and inflammatory mechanisms [4—6]. These advances have
directed clinical attention to an emergent pattern of morbidity
and mortality in patients with systemic lupus erythematosus
(SLE) related to accelerated atherosclerosis [7—9]. The long-
term therapeutic approach may now involve the use of agents
which effect not only immunologic and inflammatory, but also
atherosclerotic mechanisms. The successful treatment of the
experimental female NZBxNZW F1 lupus mouse with fish oil
(omega-3 fatty acids) dietary supplementation arouses interest
in an agent which potentially modulates inflammtory and im-
mune, as well as atherosclerotic events [10—14]. The protective
effect in the female NZBxNZW F1 mouse could be demon-
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strated with fish oil supplementation as low as 5.5% of the total
dietary fat [15]. This encouraging result prompted us to inves-
tigate the short-term effect of dietary supplementation with two
different doses of omega-3 fatty acids (MaxEPA, Scherer RP,
Windsor, Ontario, Canada) on immune, inflammatory, rheo-
logic, platelet and lipid measurements in 12 patients with SLE
and nephritis. We wanted to determine a dose of fish oil which
would be tolerated by patients with lupus nephritis and exert a
significant effect on pathogenic mechanisms known to be in-
volved in this progressively scarring disorder.
Methods
Patients
All of the patients met the revised American Rheumatism
Association criteria for the diagnosis of SLE and had a docu-
mented history of a positive anti-nuclear antibody test, at least
one elevated anti-double-stranded DNA antibody titer and
biopsy-proven kidney involvement [16]. The study was ap-
proved by the Human Ethics Committee of the University of
Western Ontario, and after the procedures were fully explained
to the patients, their informed consent was obtained. Eight of
the subjects were female and four were male, ages ranged from
25 to 48 years. All patients were receiving prednisone at doses
ranging from 10 mg on alternate days to 20 mg daily. Eight of
the 12 patients were receiving azathioprine at doses of 25 mg to
150 mg daily. Four of the 12 patients were receiving non-
steroidal anti-inflammatory drugs and were requested to discon-
tinue this medication 24 hours preceding blood and urine
testing. The prednisone and azathioprine were altered if, in the
opinion of the patient's attending physician, they experienced
an episode of disease activity. Only two patients required a
change in their prednisone medication during the 15 weeks of
the study.
Trial design
To assess the effects of a low and higher dose of fish oil on
pathogenic mechanisms in lupus nephritis, the trial was divided
into three five-week phases. The initial low dose phase was
followed by a washout period and then a higher fish oil dose
phase.
After signing the Informed Consent, 12 subjects were in-
structed to collect a 24-hour urine specimen and then to
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supplement their regular diet with two 1 g MaxEPA capsules
t.i.d. for five weeks, followed by a five week washout phase
when no MaxEPA capsules were taken. In the final phase the
subjects took six MaxEPA capsules t.i.d. for five weeks. The 1
g MaxEPA capsules (Scherer) contained 180 mg of eicosapen-
tenoic acid (EPA) and 120 mg of docosahexenoic acid (DHA).
At the beginning of the study and at the end of each phase, 65
ml of peripheral venous blood was collected for evaluation of
polymorphonuclear leukotriene B4 release, intraplatelet seroto-
nm, platelet aggregation and release, fatty acid composition of
platelet membrane phospholipids, anti-DNA antibody titer,
immune complex titer, plasma triglyceride, total, LDL, VLDL
and HDL cholesterol levels. The 24-hour urine specimens were
also collected at the initiation and at the end of each phase of
study to determine 2,3-dinor-6-oxo-PGF1 (PGI2-M), 2,3-dinor-
6-oxo-l7-ene-PGF1, (PGI3-M) and albumin excretion.
Patient compliance
Patient compliance with the fish oil supplementation was
assessed by measuring the incorporation of EPA and DHA into
platelet membrane phospholipids.
Neutrophil leukotriene B4 release
Neutrophils were isolated from heparinized whole blood by
the method of Boyum [171 and English and Anderson [181.
Heparinized blood was sedimented with 5% Dextran (10: 1) for
60 minutes. The leukocyte rich plasma was layered onto a
double gradient of Histopaque 1077/Histopaque 1119 (Sigma
Diagnostics, St. Louis, Missouri, USA) and centrifuged at 700
x g for 30 minutes at room temperature. The layer of neutro-
phils was removed, washed twice and resuspended in Hanks
balanced salt solution with 0.1% gelatin at a final concentration
of 5 x 106 cells/mI (95% neutrophil purity). The neutrophils
were stimulated with 10 molJliter of lonophore A23l87 (Cal-
biochem, La Jolla, California, USA). The suspension was
incubated for five minutes at 37°C and the reaction was stopped
by rapid cooling on ice and centrifugation at 12,000 x g for 30
seconds. The supernatants were removed and frozen at —70°C
until assayed for leukotriene B4, using the H-leukotriene B4
assay reagent system (Amersham Corp., Oakville, Ontario,
Canada). The cross reactivity of the anti-leukotriene B4 anti-
body for leukotriene B5 was less than 4%.
Platelet studies
Heparinized blood was centrifuged at 200 x g for 15 minutes.
The platelet rich plasma (PRP) was removed and the platelet
count determined with a Coulter Counter, Model ZBI (Coulter
Electronics Inc., Hilaleah, Florida, USA).
Intraplatelet serotonin
Two 500 l aliquots of PRP were diluted with 500 d of 2%
EDTA (pH 7.4) and centrifuged at 12,000 x g for five minutes.
The supernatant was aspirated off and the pellet lysed with 1 ml
distilled water and stored at —70°C. The serotonin concentra-
tion was measured by the fluorometric method of Drummond
Gordon [19].
Platelet aggregation and release
The PRP (250,00011.d) was labelled with 0.05 mCi/mi of
['4C1-serotonin (Amersham Corp.) for 30 minutes at 37°C. Four
hundred p1 aliquots of labelled PRP were pipetted into sili-
conized test cuvettes. The platelet activation was followed in a
Payton Dual Channel Aggregometer attached to a Fisher Re-
cordall 5000 Strip Chart Recorder. Collagen suspensions (bo-
vine Achilles tendon) at concentrations of 2.5, 5 and 10 tg/ml
were added to the labelled platelet suspension. The reaction
was followed for three minutes and then terminated with 100 p1
of 9.0% formalin and placed on ice. ['4C]-serotonin release was
quantitated using a beta scintillation counter LS7800 (Beckman
Instruments Inc., Ervine, California, USA) as previously re-
ported [201.
Platelet phospholipid fatty acid content
To the remaining hepannized PRP, 3.8% sodium citrate was
added (9:1). The platelets were centrifuged at 2,000 x g for nine
minutes, resuspended and washed x 3 in a wash buffer (120
mmol sodium chloride, 10 mmol sodium phosphate and 13
mmol sodium citrate, pH 6.8). The platelets were then re-
suspended in Hanks buffered salt solution and counted. One ml
containing I x iO' platelets was pipetted into a screw cap tube
and lipids were extracted using a procedure modified from that
of Bligh and Dyer [211. For this purpose, 3.5 ml methanol-
chloroform (2: 1) was added and the tube was vortexed for 60
seconds, 1.75 ml chloroform was added and followed by vor-
texing for 30 seconds. Finally, 1.75 ml distilled water was added
and vortexed for 15 seconds. The tubes were then stored at
—70°C until assayed [221. The lipid extracts (chloroform phases)
were concentrated and applied to layers of silica gel on thin
layer plates (Merck Co., Darmstadt, FRG) followed by devel-
opment in heptane : isopropyl ether: acetic acid (60:40:3, vol!
vol/vol). The bands corresponding to the different lipid fractions
were sprayed with a solution of 2,7-dichlorofluorescein (Sigma
Chemical Co.) and visualized under ultraviolet light. The phos-
pholipid band was scraped from the plates, known amounts of
monopentadecanoin (Nu-Check Prep Inc., Elysian, Minnesota,
USA) added as the internal standard and samples transmethy-
lated at 80°C with 6% H2S04 in methanol (vollvol). The
resulting fatty acid methylesters were identified by a compari-
son of their retention times to those of known fatty acid
standards, using the Hewlett Packard, Model 5890A gas chro-
matograph, equipped with a DB225 megabore column (Chro-
matographic Specialties, Brockville, Ontario, Canada). The
nitrogen flow rate was 36 mI/mm and the flame ionization
detection temperature was 250°C during these isothermal runs
[23].
Whole blood viscosity
The viscosity of heparinized whole blood relative to water
was measured using a white cell pipette at room temperature
according to the method of Wright and Jenkins [24].
Red cell deformability
Heparinized blood was centrifuged for two minutes in a Clay
Adams Autocrit (Clay Adams Co., Parsipony, New Jersey,
USA) and the voltage supplied to the centrifuge was adjusted
with a Powerstat variable transformer (Speer Electric Co.,
Bristol, Connecticut, USA) to achieve 200 g. The red cell
flexibility was measured as a percentage of cell packing/mm as
outlined by Sirs [25].
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Urinary 2,3-dinor-6-oxo-PGF,a (PGI2-M) and 2,3-dinor-6-oxo-
1 7-ene-PGF, (PGI3-M)
The 24-hour urinary excretion of PGI2-M and PGI3-M was
used as an index of the total synthesis of PGI2 and PGI3,
respectively [26, 27]. The procedures for the analysis of these
prostanoids by negative chemical ionization, capillary gas chro-
matography-mass spectrometry, have been described previ-
ously [27, 28].
Urinary albumin
Urinary albumin excretion was determined on an aliquot of
the 24-hour urine collection using a double antibody competi-
tive radioimmunoassay (Diagnostic Products Inc., Los Ange-
les, California, USA).
Anti-DNA binding activity
Anti-DNA antibody levels were quantitated using the 1251
anti-DNA radioimmunoassay kit from Amersham (Oakville,
Ontario, Canada) based on the method of Pincus and employing
reference standards established at Amersham International
Ltd. (Amersham, England, UK) [29].
Immune complex titers
Immune complex titers were quantified by the microplate
method of Pentinnen [30].
Lipid analysis
The total serum cholesterol and total serum triglyceride
concentrations were determined using enzymatic reagents ob-
tained from Boehringer-Mannheim, Montreal, Quebec, Canada
(cholesterol: CHOD-PAP; triglycerides: without free glycerol).
HDL cholesterol was determined enzymatically, as described
above following precipitation of serum with dextran sulphate,
magnesium chloride, as described by Warnick, Benderson and
Albers [31]. VLDL cholesterol and LDL cholesterol were
calculated as described by Friedwald, Levy and Fredrickson
[32].
Statistical analysis
Each subject served as his own control and thus the mean of
the different phases of the study were compared using a paired
Student's t-test, if the data were normally distributed. If the
data were not normally distributed, it was compared using a
Wilcoxon signed rank test.
Results
Patients
All patients completed the study and all demonstrated a
significant incorporation of both EPA and DHA into their
platelet membranes during the drug supplemental periods and a
decrease during the washout period (Fig. I). Two patients
underwent a change in prednisone medications during the time
of the study and two patients had very slight complaints relating
to a fishy taste and increased eructation when taking their
capsules. No patients experienced any other difficulties with the
taking of the fish oil.
Platelet aggregation
Platelet aggregation induced by decreasing concentrations of
collagen is demonstrated in Table 1. Although the platelet
aggregation declined with both the 1.1 and 3.2 g of dietary EPA
supplementation at all collagen concentrations, this achieved
significance for the 1.1 g EPA dose at the lowest collagen
concentration (P < 0.05) and for the 3.2 g dose at the highest
collagen concentration (P < 0.005).
Platelet release
The ['4C]-serotonin release reaction induced by the three
concentrations of collagen was not affected by the 1.1 and 3.2 g
of EPA dietary supplementation (Table 1).
Intraplatelet serotonin assay
The mean intraplatelet serotonin concentration (ng/109 plate-
lets) was 233.9 86.2 at initiation of the study, 186.4 106.1
after five weeks of 1.1 g of EPA supplementation, 219.7 125.5
following five weeks washout, and 249.7 77.5 after five weeks
of 3.2 g EPA dietary supplementation. The intraplatelet seroto-
nm was significantly lower (P < 0.05) after five weeks of 1.1 g
EPA treatment (Table 1).
Platelet incorporation of EPA, DHA and arachidonic acid
depletion
The fatty acid composition of the platelet phospholipids in
moles % (mean SD) is shown in Figure 1. The platelet
arachidonic acid level (20: 4w6) was significantly reduced with
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Fig. 1. Incorporation of arachidonic acid (AA), eicosapentaenoic acid
(EPA) and docosahexenoic acid (DHA) into platelet membrane (mean
SD); a = before treatment, b = after low dose treatment, c = after
washout period and d = after higher dose treatment. p = <0.0005; on
paired t-test analysis.
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Table 1. Effects of MaxEPA on urinary albumin, anti-DNA, immune complexes, blood viscosity, red cell flexibility, leukotinene B4,
and platelets
Pre-treatment
Post-low dose
treatment
After wash-
-
out period
Post-higher
dose treatment
Urinary albumin ,sg/min 616 822 436 477 699 868 897 I 168
Anti-DNA % 28 31 32 29 28 30 28 29
P.A.T.-l'complexes serum titer 23 22 25 22 25 25 25 25
Whole blood viscosity
Red cell flexibility
5.3 1.3
9.8 2.9
4.1 0.7c
13.9 55b
4.2 0.6
16.7 3.1
3,8 0,5e.h
16.9 3.6'
LT B, ag/JO6 cells 20.2 10.3 4.3 2.2" 18.3 11.0 8.6 6.4
Intra-platelet serotonin 234 86 186 106 220 126 250 78
ng/IOY platelets
Platelet aggregation (%)
Collagen dose: 10 gIml 74.2 7.1 70.6 11.6 76.2 5.7 68.8
5 tg/ml 68.6 13.4 63.8 13.1 68.5 12.4 62.5 10.3
2.5 g/ml 66.1 13.1 56.9 16.9u 65.2 16.6 55.3 17.8
Platelet release of '4C-5HT %
Collagen dose: 10 itg/ml 70.9 12.8 68.9 15.2 70.9 12.2 68.7 11.6
2.5 zg/ml 44.9 20.9 35.7 20.5 35.5 18.2 28.6 16.2
Data are mean SD; N = 12.
Pre-treatment vs. post-low dose: a P < 0.05; "P <0.01; C P < 0.005;"? < 0.001
After wash-out vs. post-higher dose: C P < 0.02; r P < 0.005; P < 0.001.
Pre-treatment vs. post-higher dose: "P < 0.005; P < 0.002; P < 0.0005.
both the 1.1 and 3.2 g of fish oil supplementation (P < 0.0005).
The EPA concentration (20:5w3) was significantly higher for
both doses of fish oil and showed a significantly greater increase
of EPA for the 3.2 g dietary supplementation than for 1.1 g dose
(P < 0.0005). A similar pattern was also detected for the DHA
(22:6w3). All subjects demonstrated a proportionate increase in
both the EPA and the DHA during their dietary supplementa-
tion and also exhibited a decrease during the washout period.
Neutrophil leukotriene B4 release
The leukotriene B4 release induced by 10 mol/liter of
ionophore A at the four different phases of the study is recorded
in Table 1. The leukotriene B4 generated (ngIlO6 neutrophils)
was not significantly different at the initiation of the study or
following the five weeks of washout period. Both low and high
doses of EPA supplementation resulted in a marked and signif-
icant decrease in the leukotnene B4 release (P < 0.001).
Whole blood viscosity
The mean whole blood viscosity for the 12 SLE nephritis
subjects was significantly reduced following five weeks of the
low dose EPA supplementation (P < 0.005). This value stabi-
lized during the five week washout and showed a further
significant fall with the increased EPA supplementation of 3.2 g
daily (P < 0.02; table 1).
Red cell flexibility
The mean red cell flexibility increased during the low-dose
fish oil supplementation (P < 0.01) and to a lesser extent during
the washout period, followed by a further slight increase with
the high dose EPA supplementation. The levels following five
weeks of high dose supplementation were significantly greater
than at the initiation of the study (P < 0.0005; Table 1).
Urinary PGI2-M and PGJ3-M
The mean urinary excretion of PGI2-M was within the range
of 150 to 180 W24 hr and was not influenced by the adminis-
tration of fish oil (Fig. 2). The urinary levels of PGI3M were
a b c d a b c d
PGI2-M PGI3-M
Fig. 2. Urinary meiabolites (mean SEM) of prostacyclin '2 (PGI2-M)
and prostacyclin I (PGI3-M); a = before treatment, b = after low dose
treatment, c = after washout period and d after higher dose
treatment. = <0.0005; on paired f-test analysis.
undetectable in the urine of most patients during the pre-
treatment and washout periods. However, they increased in a
dose-dependent fashion during the treatment periods (Fig. 2).
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Table 2. Effects of MaxEPA on plasma lipids
Plasma lipids Post-low dose After wash- Post-higher
mmol/liter Pre-treatment treatment Out period dose treatment
Total triglyceride 1.57 0.80 1.36 0.71 1.44 0.83 0.97 O.53
Total cholesterol 5.83 1.40 5.91 1.25 5.98 1.34 6.21 1.03
HDL cholesterol 1.13 0.42 1.35 0.72 1.26 0.52 1.44 0.69a
LDL cholesterol 3.99 1.22 3.94 1.10 4.07 1.20 4.32 0.88
VLDL 0.72 0.37 0.62 0.32 0.66 0.38 0.44 0.25a
cholesterol
CholesterollHDL 5.78 2.72 5.41 3.12 5.48 2.74 5.12 2.50k
P < 0.02 for pre-treatment vs. post-higher dose fish oil treatment
Lipid analysis
The mean value SD for the 12 SLE subjects for total plasma
triglyceride, total, HDL, LDL and VLDL cholesterol (mmoll
liter) are shown in Table 2. The low-dose fish oil supplementa-
tion was not associated with any significant change in lipid
levels. However, a trend was noted for an increase in HDL
cholesterol and a reduction in triglycerides in VLDL choles-
terol at the lower dose of fish oil. These changes became
significant following the higher dose of fish oil, with the triglyc-
eride dropping from 1.57 0.80 to 0.97 0.53 (P < 0.02) as
well as VLDL cholesterol from 0.72 0.37 to 0.44 0.25 (P <
0.02), with a rise in HDL cholesterol from 1.13 0.42 to 1.44
0.69 (P < 0.02). The ratio of total cholesterol to HDL choles-
terol decreased significantly (P < 0.02) from 5.78 at the begin-
fling of the study to 5.12 at the end of the higher fish oil dose.
Urinary albumin
The 24-hour urinary albumin excretion did not change with
low or high dose therapy throughout the study time period,
varying from a mean of 616 822 at initiation of study to 897
1168 at termination of the study (Table 1).
Pen tinnen immune complex assay and anti-DNA antibody
titer
There was no significant difference in immune complex titer
at any interval of the study. The mean value was elevated at 23
22 at initiation of study and 25 24.6 at termination of study.
The immune complex titer was elevated but unchanged
throughout the two fish oil phases and the washout period
(Table 1). The mean anti-DNA antibody titer was elevated at 28
at initiation of study and remained unchanged at termination of
study, demonstrating no significant alteration with the fish oil
therapy (Table 1).
Discussion
Dietary fish oil has been shown to decrease the severity of
glomerulonephritis in three different strains of lupus mice [10,
12, 33]. The precise action(s) of the fish oil which brings about
this therapeutic result is still open to conjecture. Fish oil
contains long chain, highly unsaturated omega-3 fatty acids,
principally eicosapentenoic acid (EPA) and docosahexenoic
acid (DHA). Interest is centered on the major constituent of fish
oil, EPA, although DHA appears to share some properties and
also undergoes retroconversion to EPA [34, 35]. EPA compet-
itively inhibits the production of prostaglandins and leuko-
trienes formed from arachidonic acid while acting as a substrate
for prostaglandins with three double bonds and leukotrienes
with five double bonds [36, 37]. These new trienoic prostaglan-
dins and pentaenoic leukotrienes have both altered and reduced
biologic activity [37, 38]. Omega-3 fatty acids are incorporated
into the phospholipid fractions of cell membranes, thereby
altering their fluidity, which in turn influence membrane and cell
functions [39]. Furthermore, dietary fish oil has been shown to
have a lipid lowering effect in man [40—42]. These diverse
actions may potentially alter immune, inflammatory and athero-
sclerotic events in patients with SLE [43, 44]. In this immune
disorder, Urowitz et al have described a bi-modal mortality
pattern with early events attributed to inflammatory mecha-
nisms and late events to accelerated atherosclerosis [7].
In our twelve patients with lupus nephritis, the two different
doses of fish oil (MaxEPA) were well tolerated and patient
compliance as determined by platelet EPA and DHA incorpo-
ration was dose-dependent and relatively uniform (Fig. I).
Platelet aggregation induced by collagen was inhibited at both
low and higher doses of the fish oil, whereas ['4C]-serotonin
platelet release and intraplatelet serotonin concentrations were
relatively unaffected by the dietary supplementation. Similar
changes have been noted with normal populations and have
been attributed to the incorporation of EPA into the platelet
membrane with a resultant decrease in arachidonic acid and
subsequent decrease in production of the platelet aggregant,
TXA2 [37]. We also noted an increase in EPA and DHA
incorporation into the platelet membrane with a decrease in
arachidonic acid with both the low and higher doses of the fish
oil, and this effect was reversed during the five week washout
period. The majority of the EPA and DHA was incorporated
into the platelet membranes at the lower fish oil dose and this
corresponded to the biologic membrane activity as assessed by
red cell flexibility and whole blood viscosity. The fish oil
supplementation did demonstrate a dose-dependent effect on
the red cell with an increase in red cell flexibility, and a
decrease in whole blood viscosity with the major change
occurring at the lower fish oil dose [45, 46]. We had noted a
decline in EPA and DHA incorporation into platelet membranes
during the five week washout period, but assumed the absence
of a reverse in the red cell deformability and whole blood
viscosity during the washout period was due to the much longer
half-life of the red cell relative to the platelet.
The administration of fish oil induced the biosynthesis of
PGI3 in a dose-dependent fashion. The urinary levels of PGI3-M
amounted to 4 and 15% of the levels of PGI2-M at low and
higher doses of MaxEPA, respectively, indicating that arachi-
donic acid is a better substrate than EPA for the cyclo-
oxygenase enzyme. In addition, the lack of influence of fish oil
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on the urinary excretion of PGI2-M suggests that, contrary to
the situation prevailing in vitro, EPA does not inhibit the
transformation of arachidonic acid into prostaglandin 12 in vivo
[47).
Low and higher doses of fish oil markedly reduced ionophore
A-induced neutrophil leukotriene B4 release. The effect was not
significantly different at the higher doses and was similar to that
demonstrated for higher doses of fish oil supplementation in
other human populations [36). The marked effect of low-dose
fish oil supplementation on leukotriene B4 release emphasizes
recent findings which indicate that EPA is a better substrate
than arachidonic acid for the lipoxygenase enzyme, in contrast
to the observations made with the cyclo-oxygenase enzyme
[48].
The triglyceride, total, LDL and VLDL cholesterol levels
were noted to be elevated in our lupus patients prior to dietary
supplementation with fish oil. This elevation was attributed to
the primary disease process, the heavy proteinuria and the
steroid medication the patients were receiving [49, 50]. The low
dose fish oil exerted no significant effect on the lipid levels.
However, the 3.2 g EPA supplementation resulted in a signifi-
cant decrease in triglyceride, VLDL cholesterol and ratio of
total to HDL cholesterol coupled with a significant rise in the
HDL cholesterol level. In other human populations [13, 40, 41),
dietary omega-3 fatty acids have been shown to reduce triglyc-
erides and have a variable effect on total cholesterol values. A
recent study of patients with chronic renal failure suggested fish
oil had no effect on HDL cholesterol levels [51). Although in
some studies HDL cholesterol is not increased significantly, the
majority have shown an increase with dietary fish oil supple-
mentation [40, 42, 52]. HDL cholesterol levels have been
demonstrated to correlate inversely with the risk of coronary
artery disease, but only recently has evidence indicated that an
increase in HDL levels may promote a significant protective
benefit from atherosclerotic disease. A comparison of the
Helsinki Heart Study with the LRC Study suggests this inter-
pretation [53, 54]. The LRC Study using cholestyramine and
dietary treatment showed a drop in total cholesterol of 13% and
a rise in HDL cholesterol of 3%, which equated with a 21%
reduction in definite coronary artery deaths and a 17% decrease
in all definite end-points related to coronary artery disease. This
result was compared with the Helsinki Heart Study in which
gemfibrozil with dietary treatment resulted in an 8% reduction
in total cholesterol and a 10% rise in HDL cholesterol levels.
This was associated with a 26% reduction in definite coronary
artery deaths and a 34% reduction in definite end-points for
coronary disease. These data allude to the importance of the
total to HDL cholesterol ratio and demonstrate that a rise in
HDL cholesterol is associated with a significant benefit for the
reduction of risks from coronary artery disease. Although in our
study LDL cholesterol was not significantly altered, the reduc-
tion in VLDL, triglyceride and cholesterol may confer a de-
creased risk of atherosclerosis [55).
Our subjects did not experience any increase in episodes of
disease activity during the time of the study, and the urinary
albumin levels were unaffected by the short-term treatment
with dietary fish oil. The absence of change is in keeping with
the clinical picture of ten of the twelve patients who had
significant proteinuria of greater than six months duration prior
to fish oil supplementation, and this proteinuria was thought to
be indicative of irreversible renal change. The titer of immune
complexes and anti-DNA antibody were also not influenced by
the fish oil supplementation. In the lupus mouse model, variable
effects on anti-DNA antibody titer have been reported, but
specific GP7O immune complex titers have been noted to be
decreased by this treatment [II, 12]. This apparent discordance
with our results in man may be explained by the serial obser-
vations of Kelley et al [121. She noted that early treatment with
fish oil delayed, but did not prevent, the onset of immunological
abnormalities in the experimental lupus mouse model. All of
our patients had well-defined SLE and a previous history of
immunologic abnormalities, which may preclude a reversal in
immune complex and anti-DNA antibody titer at this point in
the course of the disease.
The fish oil supplementation induced changes in platelet
aggregation, blood rheology, neutrophil leukotriene B4 release
and lipids which would favor a decrease in inflammatory and
atherosclerotic microvascular disease in the lupus nephritis
patients. The decrease in platelet aggregability induced by the
fish oil dietary supplementation could result in a decrease in
platelet endothelial interaction which is correlated with both the
formation of atherosclerotic as well as inflammatory lesions in
lupus nephritis [56, 57]. A decrease in whole blood viscosity
with an increase in red cell deformability would also be in-
volved with a reduction in platelet endothelial interaction in
atherosclerotic and inflammatory lesions [13, 581. As well, the
marked reduction in leukotriene B4 which acts as a major signal
for neutrophil and monocyte involvement in vascular damge
would be expected to attenuate both inflammatory and athero-
sclerotic lesions [13, 591. The favorable lipid changes associated
with the higher doses of EPA could reduce the atherosclerotic
risk of a group of patients who suffer a 10-fold increase in
mortality due to myocardial infarction [8, 9]. The potential of
fish oil supplementation to alter mechanisms which are co-
contributors in the pathogenesis of microvascular disease has
been demonstrated. However, our results do not indicate
whether alterations in the mechanisms which have been de-
scribed result in an amelioration in clinical outcomes for pa-
tients with lupus nephritis. In conclusion, a five week dietary
supplementation with fish oil is tolerated by patients with lupus
nephritis. The lower dose of fish oil (6 g/day) alters several
mechanisms involved in inflammatory and atherosclerotic
events but only the higher dose (18 g/day) produces a significant
change in the lipid levels.
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